An open-label , dose-optimization phase ( n = 12 ) was followed by a randomized phase ( n = 261 ) , in which patients who were HER2 positive by fluorescence in situ hybridization ( FISH ) received lapatinib 1,500 mg once per day plus once-per-week paclitaxel 80 mg/m ( 2 ) or paclitaxel alone .